Luca Mastrantoni
YOU?
Author Swipe
View article: Comparison of machine learning and deep learning models for survival prediction in early-stage hormone receptor-positive/HER2-negative breast cancer receiving neoadjuvant chemotherapy
Comparison of machine learning and deep learning models for survival prediction in early-stage hormone receptor-positive/HER2-negative breast cancer receiving neoadjuvant chemotherapy Open
View article: Nutritional Challenges in Older Cancer Patients: A Narrative Review of Assessment Tools and Management Strategies
Nutritional Challenges in Older Cancer Patients: A Narrative Review of Assessment Tools and Management Strategies Open
Background/Objectives: Malnutrition, sarcopenia, cachexia, and frailty often coexist in older cancer patients and are associated with worse treatment tolerance, reduced quality of life, and increased mortality. These syndromes can be under…
View article: Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer
Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer Open
View article: Development and Validation of Multivariable Machine‐Learning Models for the Prediction of Multisystemic Inflammatory Syndrome Outcomes in Latin American Children
Development and Validation of Multivariable Machine‐Learning Models for the Prediction of Multisystemic Inflammatory Syndrome Outcomes in Latin American Children Open
Aim We aimed to develop and test machine learning algorithms for the prediction of severe outcomes associated with MIS‐C. Method An observational ambispective cohort study was conducted including children aged from 1 month to 18 years old …
View article: Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib
Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib Open
Although retrospective, these data support the hypothesis that NRG1 VUSes are frequently associated with poor prognosis and other oncogene alterations. In EGFR M+ patients treated with osimertinib, concurrent NRG1 alterations were an indep…
View article: Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab
Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab Open
Adjuvant endocrine therapy for early breast cancer significantly reduces recurrence but increases bone fragility. Given limited data on denosumab (60 mg every 6 months) in premenopausal patients receiving endocrine therapy for early breast…
View article: Varan: a tool for managing mutational data and creating cancer studies in cBioPortal
Varan: a tool for managing mutational data and creating cancer studies in cBioPortal Open
cBioPortal has established itself as a widely used platform for exploring and visualizing multidimensional cancer data. Additionally, users have the option to upload their own cancer study for a comprehensive experience. However, the uploa…
View article: Concordance Analysis of Microsatellite Instability via NGS and Mismatch Repair Deficiency via IHC in Endometrial and Colorectal Cancer
Concordance Analysis of Microsatellite Instability via NGS and Mismatch Repair Deficiency via IHC in Endometrial and Colorectal Cancer Open
Microsatellite instability and mismatch repair deficiency are important biomarkers in colorectal and endometrial cancers, helping guide diagnosis, prognosis, and treatment decisions, particularly for immunotherapy. Mismatch repair status i…
View article: Development and Validation of Quantile Regression Forests for Prediction of Reference Quantiles in Handgrip and Chair‐Stand Test
Development and Validation of Quantile Regression Forests for Prediction of Reference Quantiles in Handgrip and Chair‐Stand Test Open
Background Muscle strength is one of the key components in the diagnosis of sarcopenia. The aim of this study was to train a machine learning model to predict reference values and percentiles for handgrip strength and chair‐stand test (CST…
View article: 236P Bone health (BH) and endocrine therapy (ET) in premenopausal early breast cancer (eBC): A real-life monocenter experience with denosumab
236P Bone health (BH) and endocrine therapy (ET) in premenopausal early breast cancer (eBC): A real-life monocenter experience with denosumab Open
View article: Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study
Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study Open
Among Luminal-HER2 negative early BCs, our results do not support a clear predictive and prognostic effect of HER2 status, although a trend of worse pCR and better survival for HER2 low BCs cannot be ruled out.
View article: COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer Open
Background: As COVID-19 has become an epidemic, we conducted an open-label study aimed to identify immunogenicity and reactogenicity of boosters of the BNT162b2 vaccine in a real-world cohort of long-survivor metastatic lung cancer patient…
View article: Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy Open
Hormone receptor-positive/HER2-negative breast cancer (BC) is the most common subtype of BC and typically occurs as an early, operable disease. In patients receiving neoadjuvant chemotherapy (NACT), pathological complete response (pCR) is …
View article: <i>POLE</i> mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single‐center cohort
<i>POLE</i> mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single‐center cohort Open
Background To date, 11 DNA polymerase epsilon ( POLE ) pathogenic variants have been declared “hotspot” mutations. Patients with endometrial cancer (EC) characterized by POLE hotspot mutations ( POLE mut) have exceptional survival outcomes…
View article: Actionable mutations in early-stage ovarian cancer according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT): a descriptive analysis on a large prospective cohort
Actionable mutations in early-stage ovarian cancer according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT): a descriptive analysis on a large prospective cohort Open
View article: The role of Mediterranean diet in cancer incidence and mortality in the older adults
The role of Mediterranean diet in cancer incidence and mortality in the older adults Open
View article: Impact of Comprehensive Genome Profiling on the Management of Advanced Non–Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program
Impact of Comprehensive Genome Profiling on the Management of Advanced Non–Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program Open
PURPOSE The clinical and research FPG500 program (ClinicalTrials.gov identifier: NCT06020625 ) is currently ongoing at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS to tailor matched targeted therapies (MTTs) according to…
View article: Scalp Cooling in Preventing Chemotherapy-Induced Alopecia for Early Breast Cancer Patients: Long-Term Outcomes of Real- Life Data
Scalp Cooling in Preventing Chemotherapy-Induced Alopecia for Early Breast Cancer Patients: Long-Term Outcomes of Real- Life Data Open
Purpose Chemotherapy-induced alopecia (CIA) negatively impacts quality of life of breast cancer patients. The present observational study was designed to confirm the efficacy and safety of scalp-cooling system to prevent CIA in early breas…
View article: To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: Final overall survival results of MONARCH 3’ by M. P. Goetz et al.
To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: Final overall survival results of MONARCH 3’ by M. P. Goetz et al. Open
View article: 42MO Interpreting somatic POLE mutations in endometrial cancer emerging from comprehensive genomic profiling
42MO Interpreting somatic POLE mutations in endometrial cancer emerging from comprehensive genomic profiling Open
View article: 5P Ovarian cancer ESCAT gene actionability: Cinderella wears the gown
5P Ovarian cancer ESCAT gene actionability: Cinderella wears the gown Open
In recent years, the prognosis of several malignancies has been positively influenced by the introduction of target therapy. In this context, ovarian cancer (OC) has played a minor role and chemotherapy still represents the backbone of sta…
View article: The role of Mediterranean diet in cancer incidence and mortality in the older adults: a systematic review and meta-analysis.
The role of Mediterranean diet in cancer incidence and mortality in the older adults: a systematic review and meta-analysis. Open
The magnitude of benefit of Mediterranean diet in cancer prevention and mortality in older adults is still unclear, therefore we conducted a systematic review and meta-analysis. Outcomes considered were cancer incidence and cancer mortalit…
View article: 254P Development of machine learning models for the prediction of early progression (EP) to first-line (1L) cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) therapy in oestrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC)
254P Development of machine learning models for the prediction of early progression (EP) to first-line (1L) cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) therapy in oestrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) Open
The combination of hormonal therapy (HT) plus CDK 4/6i represents the standard treatment for 1L ER-positive/HER2-negative MBC. Nevertheless, a small proportion of patients (pts) experiences EP within 6 months. Machine Learning (ML) techniq…
View article: Accessible Machine Learning and Deep Learning Models Predict Response and Survival in Early Stage Hormone Receptor-Positive/HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Accessible Machine Learning and Deep Learning Models Predict Response and Survival in Early Stage Hormone Receptor-Positive/HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy Open
Hormone receptor-positive/HER2 negative breast cancer (BC) is the most common subtype of BC and typically occurs as an early, operable disease. In patients receiving neoadjuvant chemotherapy (NACT), pathological complete response (pCR) is …
View article: 234P Clinical findings and genomic characterization of NRG-1 alterations with a comprehensive genome profiling (CGP) in advanced non-small cell lung cancer (ANSCLC)
234P Clinical findings and genomic characterization of NRG-1 alterations with a comprehensive genome profiling (CGP) in advanced non-small cell lung cancer (ANSCLC) Open
Fusion events involving NRG-1, a member pan-HER pathway, have been highlighted as potential therapeutic target; however, little is known about epidemiological distribution and prognostic value of NRG alterations in large real-world dataset…
View article: The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis
The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis Open
PROSPERO registration number: CRD42023389101.
View article: Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-Her2 Negative Early Breast Cancer According to Her2 Score (Low vs Score 0): A Retrospective Study
Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-Her2 Negative Early Breast Cancer According to Her2 Score (Low vs Score 0): A Retrospective Study Open
View article: Extension of the SPIRIT 2013 Statement for Factorial Randomized Trials—A Step Toward Transparency and the Curse of Interaction
Extension of the SPIRIT 2013 Statement for Factorial Randomized Trials—A Step Toward Transparency and the Curse of Interaction Open
Brennan C. Kahan, PhD; Sophie S. Hall, PhD; Elaine M. Beller, MAppStat; Megan Birchenall, BSc; Diana Elbourne, PhD; Edmund Juszczak, MSc; Paul Little, MD; John Fletcher, MPH; Robert M. Golub, MD; Beatriz Goulao, PhD; Sally Hopewell, DPhil;…
View article: 145P Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
145P Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study Open
IO ± chemotherapy (CT) is first-line therapy for mNSCLC without actionable mutations. We aimed to identify a genomic signature potentially predicting resistance to IO using NGS. Pts with mNSCLC who received IO or CT/IO were eligible. NGS w…
View article: 1679P Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
1679P Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis Open